Key result
Multiple CYP2C19, PON1, and ABCB1 mutations are linked to increased post-PCI thrombosis via higher platelet aggregation.
Why the study?
Does the presence of multiple genetic mutations in CYP2C19, PON1, and ABCB1 increase the risk of recurrent thrombosis in patients receiving clopidogrel and aspirin after percutaneous coronary intervention?
Cohort (n=263)
Does the presence of multiple genetic mutations in CYP2C19, PON1, and ABCB1 increase the risk of recurrent thrombosis in patients receiving clopidogrel and aspirin after percutaneous coronary intervention?
Assessing multiple genetic mutations (CYP2C19, PON1, ABCB1) better predicts the risk of recurrent thrombosis in patients on clopidogrel after PCI compared to CYP2C19 testing alone.
Answers are grounded in this paper and cite their sources.
Multiple mutations may influence clopidogrel response post-PCI; hypothesis-generating and requires prospective validation before guiding therapy.
Background: The effect of multiple mutations in CYP2C19, PON1 and ABCB1 genes on the effectiveness and safety of dual antiplatelet therapy after percutaneous coronary intervention remains unclear. Methods: In total, 263 Chinese Han patients were enrolled in this study. Platelet aggregation rates and thrombosis risk were used to compare clopidogrel responses and outcomes in patients with different numbers of genetic mutations. Results: Our study demonstrated that 74% of the patients carried more than two genetic mutations. High platelet aggregation rates were associated with genetic mutations in patients receiving clopidogrel and aspirin after percutaneous coronary intervention. Genetic mutations were closely related to the recurrence of thrombotic events, but not bleeding. The number of genes that become dysfunctional in patients is directly correlated with the risk of recurrent thrombosis. Conclusion: Compared with CYP2C19 alone or the platelet aggregation rate, it is more helpful to predict clinical outcomes by considering the polymorphisms of all three genes.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2023) conducted a cohort in Percutaneous coronary intervention (n=263). Multiple genetic mutations in CYP2C19, PON1 and ABCB1 genes vs. Fewer genetic mutations or CYP2C19 mutation alone was evaluated on Platelet aggregation rates and recurrence of thrombotic events. Multiple genetic mutations in CYP2C19, PON1, and ABCB1 were directly correlated with higher platelet aggregation and increased risk of recurrent thrombosis after PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: